1. Home
  2. FATE vs NOTV Comparison

FATE vs NOTV Comparison

Compare FATE & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • NOTV
  • Stock Information
  • Founded
  • FATE 2007
  • NOTV 1974
  • Country
  • FATE United States
  • NOTV United States
  • Employees
  • FATE N/A
  • NOTV N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • NOTV Biotechnology: Pharmaceutical Preparations
  • Sector
  • FATE Health Care
  • NOTV Health Care
  • Exchange
  • FATE Nasdaq
  • NOTV Nasdaq
  • Market Cap
  • FATE 133.0M
  • NOTV 137.5M
  • IPO Year
  • FATE 2013
  • NOTV 1997
  • Fundamental
  • Price
  • FATE $1.21
  • NOTV $2.60
  • Analyst Decision
  • FATE Hold
  • NOTV Strong Buy
  • Analyst Count
  • FATE 8
  • NOTV 1
  • Target Price
  • FATE $4.14
  • NOTV $5.00
  • AVG Volume (30 Days)
  • FATE 1.8M
  • NOTV 598.2K
  • Earning Date
  • FATE 05-13-2025
  • NOTV 05-07-2025
  • Dividend Yield
  • FATE N/A
  • NOTV N/A
  • EPS Growth
  • FATE N/A
  • NOTV N/A
  • EPS
  • FATE N/A
  • NOTV N/A
  • Revenue
  • FATE $13,335,000.00
  • NOTV $480,402,000.00
  • Revenue This Year
  • FATE N/A
  • NOTV $5.57
  • Revenue Next Year
  • FATE N/A
  • NOTV $5.23
  • P/E Ratio
  • FATE N/A
  • NOTV N/A
  • Revenue Growth
  • FATE 105.85
  • NOTV N/A
  • 52 Week Low
  • FATE $0.66
  • NOTV $1.15
  • 52 Week High
  • FATE $5.92
  • NOTV $6.48
  • Technical
  • Relative Strength Index (RSI)
  • FATE 53.44
  • NOTV 58.71
  • Support Level
  • FATE $1.12
  • NOTV $1.96
  • Resistance Level
  • FATE $1.38
  • NOTV $2.96
  • Average True Range (ATR)
  • FATE 0.12
  • NOTV 0.24
  • MACD
  • FATE 0.01
  • NOTV 0.08
  • Stochastic Oscillator
  • FATE 62.22
  • NOTV 64.00

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: